selinexor
Xpovio Approved to Treat RRMM After 1 Prior Therapy
The FDA approved selinexor (Xpovio, Karyopharm) in combination with bortezomib and dexamethasone for the treatment ...
DECEMBER 22, 2020
Once-Weekly Regimen for R/R Multiple Myeloma Found Beneficial in Boston Trial
A regimen of selinexor and bortezomib once weekly combined with twice-weekly dexamethasone is an effective ...
NOVEMBER 27, 2020
BTK Inhibitors, Other Blood Cancer Drugs Are Being Tapped for COVID-19
Studies are underway exploring immunomodulating agents approved for hematologic malignancies in the treatment of ...
JULY 23, 2020
Xpovio Approved to Treat Relapsed or Refractory DLBCL
The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm) for the treatment of adult patients with ...
JUNE 23, 2020
Xpovio Approved to Treat Relapsed/Refractory MM
The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm) in combination with dexamethasone for the ...
AUGUST 5, 2019
FDA Advisory Committee Rejects Selinexor for MM, Wants More Data
The ODAC voted 8 to 5 recommending that the FDA wait for the results from the randomized, open-label, phase 3 ...
MARCH 5, 2019